Tear Sheet

Print Page   Print Page       E-mail Page   Email Page       RSS Feeds   RSS       E-mail Alerts  Email Alerts       Financial Tear Sheet  Tear Sheet

Tear Sheet

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. 

Press Releases
Date Title
03/17/20 Statement from Alkermes on Response to COVID-19
03/04/20 Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study of ALKS 3831 in Patients With Schizophrenia
02/24/20 Alkermes Response to Media Coverage of the Company and VIVITROL
02/24/20 Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 40th Annual Health Care Conference
02/19/20 Alkermes to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

SEC Filings

Filing date Description

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities